At meeting on human embryo editing, CRISPR pioneer says science is a long way from knowing if germline DNA can be safely ...

CRISPR Therapeutics (NasdaqGM:CRSP) recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction.

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

Epicrispr Biotechnologies has raised $68m in the initial close of its Series B financing round to commence the clinical trial ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...

Crispr Therapeutics said Chief Operating Officer Julianne Bruno would depart the company to pursue other opportunities, effective April 11. Bruno joined the gene-editing company in 2019 and stepped ...

Crispr Therapeutics (CRSP) announced that its COO, Julianne Bruno, will be stepping down from the company to pursue external opportunities, ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon ...

The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several drugmakers.

Avantax Advisory Services Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and ...